Caroline Loew, Mural Oncology CEO

Mur­al On­col­o­gy spins out from Alk­er­mes with $275M and a lead im­munother­a­py pro­gram

Mur­al On­col­o­gy is spin­ning out of Alk­er­mes with $275 mil­lion and a lead im­munother­a­py can­di­date al­ready in two stud­ies in mu­cos­al melanoma and ovar­i­an can­cer.

On top of the fund­ing, Alk­er­mes is al­so dis­trib­ut­ing Mur­al stock to its share­hold­ers — one Mur­al share for every 10 Alk­er­mes shares they own.

The com­pa­ny will start trad­ing on the Nas­daq on Nov. 16 un­der $MU­RA. Its lead drug, an in­ter­leukin-2 (IL-2) cy­tokine dubbed nem­valeukin al­fa, is al­ready in two reg­is­tra­tional stud­ies in mu­cos­al melanoma as a monother­a­py and an­oth­er for plat­inum-re­sis­tant ovar­i­an can­cer in com­bi­na­tion with pem­brolizum­ab (Keytru­da). Topline da­ta are ex­pect­ed for both in the first quar­ter of 2025.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.